雷帕霉素洗脱支架在冠心病合并2型糖尿病患者中的应用

目的 评估冠心病合并2型糖尿病患者冠状动脉内植入雷帕霉素洗脱支架的临床疗效。方法155例冠心病合并2型糖尿病患者接受冠状动脉内支架术，其中81例植入雷帕霉素洗脱支架（SES组），74例接受普通金属裸支架（BMS组），比较两组的临床一般情况、冠脉造影、支架植入术和远期综合心脏事件发生率。结果两组患者冠脉病变特点和支架植入术情况无统计学差异（P〉0．05），住院期间均无严重并发症发生。平均随访1年中，SES组远期心脏不良事件发生率显著低于BMS组（P〈0．001）。结论冠心病合并2型糖尿病患者植入雷帕霉素洗脱支架安全有效；与普通金属裸支架相比，雷帕霉素洗脱支架能显著降低心脏不良事件发生率。

Application of Sirolimus-Eluting Stents in Patients with Coronary Artery Disease and Type 2 Diabetes

Objective This study evaluated the outcomes of sirolimus-eluting stents in patients with coronary artery disease and type 2 diabetes. Methods Among 155 patients with coronary artery disease and type 2 diabetes underwent percutaneous coronary intervention, 81 received sirolimus-eluting stents (SES group) and 74 were treated only with bare metal stents (BMS group). Baseline clinical characteristics, procedural success rate and occurrence of cardiac events during follow-up were recorded and compared between the two groups. Results During hospitalization no patient had complications. At one year follow-up, SES group had lower occurrence of cardiac events than BMS group (P<0.001). Conclusion Sirolimus-eluting stent implantation for patients with coronary artery disease and type 2 diabetes is safe and can reduce major adverse cardiac events in long-term follow-up.